| Trial ID: | L0662 |
| Source ID: | IRCT201109197590N1
|
| Associated Drug: |
Ezetimibe
|
| Title: |
Comparison the effect of ezetimibe and acarbose on biochemical indices in patient with nonalcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
non alcoholic fatty liver disease. <br>Fatty (change of) liver;Fatty (change of) liver
|
| Interventions: |
Intervention 1: 50 mg acarbose 3 times per day, oral, in acarbose group. Intervention 2: 10 mg ezetimibe once per day, oral, in ezetimibe group.;Treatment - Drugs;Treatment - Drugs;50 mg acarbose 3 times per day, oral, in acarbose group;10 mg ezetimibe on
|
| Outcome Measures: |
Liver enzyme, AST, aspartate aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.;Liver enzyme, ALT, alanine aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.Insulin resistance index. Timepoint: Before and 2months after treatment. Method of measurement: Fasting glycemia mmol/L?? fasting insulinemiaMIU/L/22 .lab kit.;Inflamation index hs CRP. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.
|
| Sponsor/Collaborators: |
Vice chancellor for research, Qazvin University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 yearsno limit
|
| Phases: |
Phase 2
|
| Enrollment: |
31
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.
|
| Start Date: |
23/12/2011
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/8080
|
